NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company that develops botanical drugs for the treatment of addictions and dependencies, has been informed of the exercise of 50,000 business creator warrants (“BSPCE ”) held by Mr. Bruno Lafont, Deputy CEO and co-founder of NFL Biosciences, giving him the right to subscribe to 500,000 new shares which will allow him to strengthen his stake in the capital of the company he co-founded in 2006. Bruno Lafont now holds 8.86% of the capital of NFL Biosciences, against 4.18% before the operation.
The 50,000 BSPCE 2018 held by Mr. Lafont were exercised in full on July 5, 2023, before their maturity date of July 2, 2025. They enabled him to subscribe to 500,000 new shares at a price of 0.10 euro, generating a contribution of €50,000 for NFL Biosciences.
Since 2006, Bruno Lafont has been in charge of the structuring and development of NFL Biosciences, which he co-founded. Within the management team of NFL Biosciences, he manages in particular the implementation of clinical studies and the scientific activities of the company.
As part of his asset management, prior to the exercise of his BSPCE, Mr. Lafont sold 100,000 NFL Biosciences shares on the Euronext Growth Paris market at an average price of 2.6 euros. These transactions were declared today to the AMF, in accordance with stock market regulations.